T1期膀胱癌中端粒酶逆转录酶突变与p53通路的关系
这项前瞻性人群研究纳入瑞典东南医疗区1992-2001年登记的158例T1期膀胱癌患者,检测TERT突变、p53突变及p53免疫组化(阈值10%和50%)。TERT突变见于47%患者,p53突变见于30%。TERT突变在p53突变阳性患者中更常见,TERT突变阴性时p53突变与更短进展时间相关,而TERT与p53双突变阳性时p53 IHC50%阳性者进展时间更长。
要点
- T1期膀胱癌中TERT突变率47%,p53突变率30%。
- TERT突变与p53突变阳性相关(P=0.009)。
- TERT突变可能对p53突变诱导的进展有保护效应。
核心结论
- 在T1期膀胱癌中,TERT突变与p53突变的组合与肿瘤进展相关。
- TERT启动子突变可能对p53突变及后续p53积累诱导的肿瘤进展具有保护效应,但需进一步研究。
研究设计与样本
- 前瞻性人群为基础的研究,纳入瑞典东南医疗区1992-2001年登记的T1期膀胱癌患者158例。
- 评估TERT突变、p53突变,并进行p53免疫组化分析,采用10%和50%两个阳性阈值。
- 采用Cox比例风险分析和Kaplan-Meier曲线研究肿瘤进展时间。
主要发现
- 158例患者中,TERT突变74例(47%),p53突变48例(30%),p53 IHC50%阳性72例(46%)。
- TERT突变在p53突变阳性患者中更常见(P=0.009),后者p53 IHC50%阳性肿瘤细胞也更多(P=0.02)。
- 在TERT突变阴性的肿瘤中,p53突变阳性与更短的进展时间相关(P=0.03)。
- 在TERT突变阳性且p53突变阳性的肿瘤中,p53 IHC50%阳性组进展时间更长。
临床怎么用
- T1期膀胱癌中可联合检测TERT突变、p53突变及p53 IHC50%以评估进展风险。
- TERT突变状态可能影响p53突变患者的风险分层,但尚需进一步验证。
局限性
- 样本量有限(158例),结论需更大规模研究确认。
- TERT突变对p53通路的保护效应仅为可能,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the telomerase reverse transcriptase (TERT) mutation and the p53 pathway in T1 urinary bladder cancer (UBC). MATERIALS AND METHODS: This prospectively performed population-based study included all patients in the Southeast Healthcare Region in Sweden with T1 UBC registered in the period 1992-2001, inclusive. Given that p53 and TERT are important factors for tumour proliferation, although their interrelationships are unknown, we assessed both the TERT and the p53 mutations. Furthermore, we conducted a p53 immunohistochemistry (IHC) analysis using two thresholds for p53 positivity: 10% of tumour cells and 50% of tumour cells (p53 IHC50%). Cox proportional hazards analysis and Kaplan-Meier curves were used to study time to tumour progression. RESULTS: Out of 158 patients, we observed the TERT mutation in 74 (47%), the p53 mutation in 48 (30%), and p53 IHC50% positivity in 72 patients (46%). The TERT mutation was more common in p53 mutation-positive patients (P = 0.009), and the latter group also had more patients with p53 IHC50%-positive tumour cells (P = 0.02). In the TERT mutation-negative tumours a p53-positive mutation was associated with a shorter time to progression (P = 0.03) compared to patients with p53-negative mutation. In contrast, in tumours with both TERT mutation positivity and p53 mutation positivity, a longer time to progression was observed in the group with p53 IHC50% positivity compared to the group with p53 IHC50%-negative tumours. CONCLUSIONS: In stage T1 UBC, the combination of the TERT mutation and the p53 mutation was associated with tumour progression. A protective effect of the TERT promotor mutation against tumour progression induced by the p53 mutation and subsequent p53 accumulation in tumour cells might be possible, but further investigations are necessary.
引用
- Jahnson S, Söderkvist P, Aljabery F, et al. Telomerase reverse transcriptase mutation and the p53 pathway in T1 urinary bladder cancer. BJU Int. 2021. PMID: 34028171. doi:10.1111/bju.15490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。